Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism

Nephrology

Volumn 14, Issue 5, 2009, Pages 488-492

  Abdul Gafor, Abdul Halim ^a,b   Saidin, Rashidi ^a   Loo, Chee Yean ^a   Mohd, Rozita ^a   Zainudin, Soehardy ^a   Shah, Shamsul Azhar ^a   Norella, Kong Chiew Tong ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Calcium; Calcium phosphorus product; Haemodialysis; Parathyroid hormone; Phosphate

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; CALCITRIOL; CALCIUM; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PHOSPHATES; RENAL DIALYSIS;

EID: 68349085822     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01058.x     Document Type: Article

References (22)

1. Salem MM. Hyperparathyroidism in the hemodialysis population: A survey of 612 patients. Am. J. Kidney Dis. 1997 29 : 862 5.
2. Slatopolsky E, Caglar S, Pennell JP et al. On the pathogenesis of hyperparathyroidism in chronic experimental insufficiency in the dog. J. Clin. Invest. 1971 50 : 492 9.
3. Olafur SI, Darryl LQ. Comparison of treatment for mild secondary hyperparathyroidism in hemodialysis patients. Kidney Int. 2000 57 : 282 92.
4. Daisey-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy 1996 16 : 619 30.
5. Block G, Port FK. Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease. Semin. Dial. 2003 16 : 140 47.
6. Tuma SN, Martin RR, Malette LE, Eknoyan G. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J. Lab. Clin. Med. 1981 97 : 291 8.
7. Schucker JJ, Ward KE. Hyperphosphataemia and phosphate binders. Am. J. Health Syst. Pharm. 2005 62 : 2355 61.
8. Andress DL. Intravenous versus oral vitamin D therapy in dialysis patients. What is the question? Am. J. Kidney Dis. 2001 38 : 41 4.
9. Quarles LD, Yohay DA, Carroll BA et al. Prospective trial of pulse oral versus intravenous calcitriol in the treatment of hyperparathyroidism in ESRD. Kidney Int. 1994 45 : 1710 21.
10. Goodman WG, Ramirez JA, Belin TR et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994 46 : 1160 66.
11. Slatopolsky E, Finch J, Ritter C et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis. 1995 26 : 852 60.
12. Lindberg J, Martin KJ, Gonzales EA et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end stage renal disease. Clin. Nephrol. 2001 56 : 315 23.
13. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003 63 : 1483 90.
14. 3 on the intestinal calcium and phosphate transport. J. Lab. Clin. Med. 2002 139 : 279 84.
15. Yakahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25(OH)2D2, 19-nor-1,25(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am. J. Kidney Dis. 1997 30 : 105 12.
16. Massry SG, Coburn JW, Lee DB, Jowsey J, Kleeman CR. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003 42 (Suppl 3 S1 201.
17. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004 15 : 2208 18.
18. Lim YN, Lim TO (eds). Fourteenth Report of Malaysian Dialysis and Transplantation Registry 2006: All Renal Replacement Therapy in Malaysia. Fourteenth Report of Malaysian Dialysis and Transplantation Registry 2006. Kuala Lumpur : The National Renal Registry, 2007 1 3.
19. Martin KJ, Gonzales EA, Gellens ME, Hamm LL, Abboud H, Lindberg J. Therapy of secondary hyperparathyroidism with 19-nor-1-alpha-25-dihydroxyvitamin D2. Am. J. Kidney Dis. 1998 32 : S61 6.
20. Martin KJ, Gonzales E, Lindberd JA et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blind, multicenter, randomized study. Am. J. Kidney Dis. 2001 38 (Suppl 5 S57 63.
21. Mitsopoulos E, Zanos S, Ginikopoulou E et al. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 2006 48 : 114 21.
22. Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uraemic patients. J. Clin. Invest. 1993 92 : 1436 43.